The United States Food and Drug Administration (USFDA) has completed an inspection at Aurobindo Pharma’s wholly owned subsidiary -- Auroactive Pharma’s manufacturing facility, which manufactures Active Pharmaceutical Ingredients (API) & Pharmaceutical Formulation Intermediates, situated at Sy Nos 231, 285 to 291, Sancham Village, Ranasthalam Mandal, Srikakulam, Andhra Pradesh, from June 22, 2026, to June 26, 2026. The inspection concluded with 2 observations and will be responded to within the stipulated time.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
